Primrose Bio's $15M Bet: Manufacturing Tools Over Single Therapies

Primrose Bio sold nearly $15M of equity in 2024 to expand a set of manufacturing technologies for protein and nucleic-acid medicines — a deal that says less about any single drug than about the production systems behind many of them.

The San Diego company announced 1315 Capital's investment on June 17, 2024 without naming the amount. An SEC Form D later supplied the transaction math: $15M sold to two investors in an equity offering that could reach $22,999,995, with $7,999,996 remaining. The second investor was not identified in the filing. Secondary databases sometimes label the transaction a Series B, but the company announcement, the Form D and 1315 Capital's portfolio page do not use that label, so it is best treated as a growth-equity financing with no verified series designation.

The proceeds were earmarked for continued development and commercial expansion of three offerings: Prima RNApols, Pfenex Expression Technology and PeliCRM197. Each sits at a different point in the biologics-manufacturing stack, but the commercial argument is consistent — better production tools can reduce the friction between a scientific result and a repeatable process.

Prima RNApols are engineered RNA polymerase enzymes for mRNA manufacturing. In the financing announcement, Primrose Bio said the enzymes could improve yields by as much as 5x, remove double-stranded RNA and improve cap incorporation compared with the standard T7 polymerase. Those are company-reported performance claims, not independent benchmarks, but they show why polymerase selection can affect both output and downstream cleanup.

Pfenex Expression Technology is a microbial expression platform built on Pseudomonas fluorescens for complex proteins. Primrose Bio reported 10x to 20x higher yields than E. coli, CHO and yeast systems in its 2024 announcement. The company's current product page says the platform supports six approved biologics, more than 25 global technology transfers and more than 200 lead proteins generated. PeliCRM197 is a carrier protein used in conjugate-vaccine development and commercial products.

The financing also came with a valuation reset. Ligand Pharmaceuticals reported that its ownership in Primrose Bio declined from 49.9% to 34.3% and that the round was priced below the valuation used when Primrose Bio was formed in September 2023. That does not erase the strategic case for new capital, but it shows that commercializing a manufacturing platform still has to survive ordinary financing discipline.

Primrose Bio was established in 2023 by combining Primordial Genetics with Ligand's Pelican/Pfenex protein-expression assets and the PeliCRM197 franchise. At the time of the 1315 Capital investment, Primordial Genetics founder Helge Zieler was Primrose Bio's CEO. The company appointed Drew Burch as CEO in October 2025, citing his experience commercializing biomanufacturing technologies at Maravai LifeSciences and Thermo Fisher Scientific. Zieler is now listed as an advisor, and 1315 Capital partner Matt Reber serves on the board.